logo
ICE Detainee Dies After HIV Undiagnosed for Months During Custody

ICE Detainee Dies After HIV Undiagnosed for Months During Custody

Newsweek02-05-2025

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A man who died in ICE custody earlier this year from complications related to untreated HIV could have been saved with the help of routine blood tests, medical experts have told Newsweek, raising concerns about health screening in detention facilities.
The 45-year-old Ethiopian man died on January 29, 2025, from "Complications of multiple infections in the setting of human immunodeficiency virus," according to a medical examiner's report filed two days later.
His condition went unaddressed during his nearly 4-month detention at Eloy Detention Center in Arizona, a death report from immigration officials said. Modern HIV treatments allow near-average life spans.
Three leading infectious disease epidemiologists told Newsweek opportunities to save the man's life were missed.
Perry Halkitis, professor of public health at Rutgers University, said "routine blood work" tests would have "immediately" shown that he had HIV.
Denis Nash, professor of epidemiology at the CUNY School of Public Health, said the death appeared "entirely preventable" if diagnosed and treated at the time of his initial medical exam, and "still possible" after he started to develop symptoms of advanced HIV.
Dr. Monica Gandhi, director of the UCSF Gladstone Center for AIDS Research, also said that antiretroviral therapy during custody "could have prevented" the man's death.
When contacted by Newsweek about the concerns, Immigration and Customs Enforcement (ICE) said its 1,600-strong ICE Health Service Corps employees "uphold the highest standards" and follow the latest Performance-Based National Detention Standards to provide "comprehensive medical care," including a full health assessment for detainees within 14 days.
Photo-illustration by Newsweek/Getty
Detainees do not need to be routinely screened for HIV, those standards show, but "may request HIV testing at any time during detention" and an HIV diagnosis "may be made only by a licensed health care provider, based on a medical history, current clinical evaluation of signs and symptoms and laboratory studies."
Nurses twice recorded the man denied having any prior medical history, the death report said.
"At no time during detention is a detained individual denied emergent care," ICE added.
The detention center's operator, CoreCivic, told Newsweek its staff would not have made medical decisions and are trained to refer all detainee health concerns to medical staff, and that safety, health, and well-being "is our top priority."
The documents detailing the man's death were first obtained by the nonprofit watchdog Project On Government Oversight.
The man has not been named due to uncertainty about whether his family was aware of his HIV condition.
Why It Matters
The death raises serious questions over medical care for those in ICE custody. It also raises concerns about the lack of routine HIV screening in ICE facilities, which experts say could have prevented this tragedy.
Between fiscal years 2018 and 2025, there were 65 reported deaths in ICE detention facilities.
Immigration arrests and detention have risen sharply under President Donald Trump's second term, leaving stretched detention centers at maximum capacity.
What to Know
The man was arrested by the U.S. Border Patrol near Lukeville, Arizona, on August 19 last year after entering the country illegally. He was placed into expedited removal proceedings and transferred to ICE custody at Eloy Detention Center.
No HIV treatment was provided during his time in custody, even though his condition would have required specialized medical attention.
After an initial medical screening, which included a chest X-ray, on August 21 and 22, the detainee was cleared to be housed in the general population of the facility, ICE's death report said.
The man was evaluated for back pain four times between November 3 and December 16, the death report shows.
On December 20, the man informed a detention staff member he had fainted in the recreation yard the day before.
A medical doctor assessed him and noted the man showed normal vital signs but also signs of dehydration, an elevated pulse reading of 130 bpm, was feeling weak and fatigued and had lost about 20 percent of his body weight. He was referred to Banner Casa Grande Hospital.
Between Christmas Eve and New Year's Ever, doctors at the hospital diagnosed acute respiratory distress, pneumonia, possible lymphoma, and a pericardial effusion, and provided treatment.
He was taken by air ambulance to an intensive care unit at Banner University Medical Center Phoenix's (BUMCP) on December 31.
Between New Year's Day and January 2, BUMCP medical staff identified his immunocompromised status—HIV can leave the body unable to produce an adequate immune response — and diagnosed him with acute respiratory distress, pneumonia, possible lymphoma with metastases in the lungs, life-threatening sepsis, supraventricular tachycardia, and ischemic stroke. As a result, BUMCP medical staff ordered oncology and palliative care consultations.
On January 3, BUMCP medical staff performed a biopsy of his neck lymph node, diagnosed him with tuberculosis, and placed him on a ventilator for airway protection
As his condition continued to deteriorate, his next of kin made the decision to withdraw life support.
The man was pronounced dead at approximately 1:21 p.m. on January 29.
Medical experts told Newsweek that better treatment could have prevented the man's death.
"This patient died of AIDS and resultant opportunistic infections that result from untreated HIV infection, including central nervous system toxoplasmosis, pneumocystis pneumonia, tuberculosis, and CMV (all infections that occur as a result of advanced immunodeficiency with HIV)," said Dr. Gandhi after reviewing the medical examiner's report.
"He was not receiving antiretroviral therapy (which treats HIV) when in ICE detention which could have prevented all of these conditions."
Nash, professor of epidemiology at the CUNY School of Public Health, said the death appeared "entirely preventable" if recognized and diagnosed in time.
"It is possible that [the detainee] could have survived, had his HIV been diagnosed and treated at the time of his initial medical exam, and also still possible even after he started to develop symptoms of advanced HIV and OIS."
He added: "The presence of multiple opportunistic infections—like pneumocystis pneumonia, CMV, toxoplasmosis, and advanced TB—strongly suggests he had untreated HIV for a long time. These are not subtle signs; they are classic indicators of HIV infection that has progressed to full-blown AIDS due to a severely weakened immune system.
"And development of new symptoms after detention should receive immediate attention, as both advanced HIV and TB disease can progress rapidly towards a fatal outcome without treatment."
It is still common for people to be diagnosed too late to benefit from treatment, Nash said, and clinical management is harder when people have advanced HIV and other complications.
"Even when this happens, people can often respond well to treatment of HIV and the OIS. But time is of the essence. And of course clinical management is harder when people have advanced HIV with Oi-related complications like this," he said.
This electron microscope image made available by the U.S. National Institutes of Health shows a human T cell, in blue, under attack by HIV, in yellow, the virus that causes AIDS.
This electron microscope image made available by the U.S. National Institutes of Health shows a human T cell, in blue, under attack by HIV, in yellow, the virus that causes AIDS.
Seth Pincus, Elizabeth Fischer, Austin Athman/National Institute of Allergy and Infectious Diseases/NIH via AP
Halkitis, an expert in infectious disease epidemiology and professor of public health at Rutgers University, said in a statement: "If they had run routine blood work they would have seen immediately from his CD4 [a type of white blood cell that plays a crucial role in the immune system] count that he had HIV. Immediately!"
Public health experts have repeatedly raised alarms about inadequate infectious disease screening in immigration detention centers.
A study published in Health and Human Rights Journal in 2009 concluded "the system of immigration detention in the US fails to adequately screen detainees for HIV and delivers a substandard level of medical care to those with HIV."
The study urged ICE to adopt routine HIV testing to all detainees, provide appropriate care to those who require treatment, report HIV statistics to an external agency, and guarantee defined medical care as a matter of law.
A 2024 study in the American Journal of Public Health called on ICE to improve access to HIV treatment and begin publishing monthly health care metrics—including data on whether detainees are receiving HIV medications.
Immigration arrests and detention have risen sharply since Trump began his second White House term on January 20.
U.S. ICE agents made 32,809 migrant arrests between then and March 10, 2025, officials said at a news conference in March, at a rate more than double than under former President Joe Biden.
Detention centers are struggling to cope. U.S. immigration detention is filled to capacity at 47,600 detainees, a senior ICE official told reporters that month, and the Trump administration is seeking more bed space.
The Elroy facility had the sixth highest daily population on January 6, according to data analyzed by Syracuse University nonprofit TRAC.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Yahoo

time2 hours ago

  • Yahoo

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Business Wire

time2 hours ago

  • Business Wire

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). Results demonstrated an overall response rate (ORR) of 87 percent, a complete response (CR) rate of 65 percent and a partial response (PR) of 23 percent. The majority of patients (65 percent) proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30 th European Hematology Association (EHA) 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome (CRS) being low grade and no discontinuations due to treatment-emergent adverse events (TEAEs). The most common TEAEs were neutropenia (74 percent), anemia (68 percent), and thrombocytopenia (68 percent). CRS occurred in 52 percent; all were low grade (1/2) and resolved. One patient had immune effector cell-associated neurotoxicity syndrome (ICANS; grade 1), which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients (58 percent); five (16 percent) had serious infections. There were no Grade 5 TEAEs. 'These results are particularly encouraging because many of the patients in this study had high-risk disease, having progressed rapidly after initial treatment,' said Raul Cordoba, MD, PhD, Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. 'This combination therapy of epcoritamab plus rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) offers a potential new treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma, providing high response rates and a bridge to potentially curative autologous stem cell transplantation." Among patients in the study who progressed within 12 months after first-line treatment (n=20), epcoritamab in combination with R-ICE demonstrated an 85 percent ORR and 55 percent CR. Patients in the study who progressed after 12 months from first-line therapy experienced a 91 percent ORR and 82 percent CR. Additionally, patients with one prior line of therapy experienced an 88 percent ORR and 68 percent CR, and patients who were treated with more than one prior line of therapy experienced an 83 percent ORR and 50 percent CR. 'The results from this trial highlight the potential of this investigational epcoritamab containing regimen, especially in patients who progress quickly after initial treatment, and reinforce our joint efforts with AbbVie to develop epcoritamab as a core therapy for B-cell lymphomas, especially as we develop epcoritamab in earlier lines of therapy and a broader patient population,' said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. 'Our comprehensive EPCORE clinical trial program is dedicated to advancing epcoritamab as both monotherapy and in combination to address the significant unmet need in relapsed/refractory diffuse large B-cell lymphoma and other hematologic malignancies." Use of epcoritamab + R-ICE in patients with R/R DLBCL eligible for ASCT is not approved and the safety and efficacy of epcoritamab for use as a combination therapy in DLBCL have not been established. About Diffuse Large B-Cell Lymphoma DLBCL is the most common type of non-Hodgkin's lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases. In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year. DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men. DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge. About the EPCORE ® NHL-2 Trial EPCORE NHL-2 is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin's lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary endpoint was overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint. Arm 10 of the EPCORE NHL-2 study enrolled 31 patients with R/R DLBCL, who were eligible for R-ICE and ASCT, and had received ≥1 prior line of treatment. At the time of data cutoff (December 18, 2024), median follow-up was 11 months (range, 6−15). Among the 31 patients treated with epcoritamab 48 mg + R-ICE, 61 percent were Ann Arbor stage III/IV, 42 percent had bulky disease ≥7 cm, 81 percent had one prior LOT (range, 1−3), and 65 percent had progressed within 12 months of first-line treatment. More information on this trial can be found at (NCT: 04663347). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. i Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Where approved, epcoritamab is available as a readily accessible therapy without the need for reducing tumor burden ('debulking'). Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigators choice chemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with R/R FL (NCT05409066), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with R2 compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit for more information. EPKINLY ® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. Important Warnings—EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Full Prescribing Information and Medication Guide, including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ®) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and X. This Media Release contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSO™. EPCORE ®, EPKINLY ®, TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine

Historic Aussie-first breakthrough in fight against condition impacting 40 million
Historic Aussie-first breakthrough in fight against condition impacting 40 million

Yahoo

time13 hours ago

  • Yahoo

Historic Aussie-first breakthrough in fight against condition impacting 40 million

In a groundbreaking leap forward in the global fight against HIV, researchers at Melbourne's world-renowned Doherty Institute have developed a revolutionary method that could one day pave the way for a cure, using the same mRNA technology that powered COVID-19 vaccines. This discovery gives fresh hope to the nearly 40 million people around the world living with HIV. While today's treatments can keep the virus under control, they can't remove it completely. That's because HIV hides in a type of white blood cell, staying asleep and undetectable. But if treatment stops, the virus can wake up and spread again. For decades, this hidden "reservoir" has been one of the biggest obstacles to finding a cure. Now, researchers believe they've found a way to reach these sleeping cells and wake the virus up in a safe and controlled way, while the patient is still on their usual medication. Speaking to Yahoo News Australia, Dr Michael Roche, a Senior Research Fellow at the Doherty Institute, explained how his team used mRNA wrapped inside tiny fat-like bubbles called lipid nanoparticles. These nanoparticles are designed to travel directly to infected cells. Once inside, the mRNA sends instructions to the cell to make a protein called Tat — a natural HIV protein that tells the virus it's time to wake up. "Tat is a protein that helps the virus 'wake up' when the virus wants to," Dr Roche said. "Here we are using Tat to wake the virus up when we want to." This process is often called the "shock and kill" strategy. The idea is to force the virus out of hiding while the patient is still on HIV medication, so the virus can't spread and can instead be targeted and destroyed by the immune system or future therapies. The discovery is still in early stages, but it's the first time mRNA has successfully reached and activated the HIV reservoir in a lab setting. The team's next step is to test the treatment in animal models to check if it's safe and if it works. "We are looking for two signals," Dr Roche said. "Firstly, safety. Secondly, efficacy — whether it can wake up dormant HIV in animals." These trials will take a few years. Only after passing those tests can human trials begin — first to ensure the treatment is safe, and then to test how well it works in people. A key advantage is that this therapy uses the same technology that powered the COVID-19 vaccine rollout. "Our therapeutic is based on the same technology — mRNA and lipid nanoparticles — used in the COVID vaccines," Dr Roche said. "The global rollout of these vaccines has shown that this approach can be scaled and distributed globally." He pointed to a new BioNTech mRNA facility in Rwanda, which is being set up to support production in areas with a high burden of HIV. The team is also focused on making sure the treatment, if successful, can be made affordable and accessible. "We are committed to ensuring any cures we develop are scalable, accessible and affordable," Dr Roche said. Aussies warned over widespread danger emerging in homes Concerning roadside find reveals dangerous trend landing Aussies in hospital Controversial 'alcohol alternative' coming to Woolworths this month In Australia, around 29,000 people are living with HIV. New infections have dropped over the past decade thanks to wider access to HIV prevention medication (PrEP), regular testing, and strong treatment programs. The country recorded its lowest number of new HIV cases in over 20 years in 2022. But some challenges remain. In 2023, there was a slight increase in new cases, mostly among people born overseas and those infected through heterosexual contact. Still, the long-term trend is positive, and now, with this research, a cure no longer feels out of reach. If successful, this approach could one day mean people living with HIV no longer need daily medication, and may even be able to live completely free of the virus. As the world watches closely, Australia's scientists are once again leading the charge. Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store